Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financi...( Launch of First Three Diagnostic...)

Launch of First Three Diagnostic Tests Based on Company's microRNA

Technology on Schedule for 2008

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading molecular diagnostics company, today reported a narrower operating loss per ordinary share for the fourth quarter of 2007 compared with corresponding period of 2006, and said it remains solidly on target for the launch of the first three diagnostic tests based on the company's proprietary microRNA technology, this year.

2007 fourth-quarter operating loss of $3.5 million (including a non-cash expense of $311,000 related to stock based compensation), or $0.30 per ordinary share compares with an operating loss of $2.2 million (including a non-cash expense of $302,000 related to stock based compensation), or $0.87 per ordinary share, for the corresponding quarter of 2006. Operating loss for the year ended December 31, 2007, was $11 million (including a non-cash expense of $1 million related to stock based compensation), or $0.99 per ordinary share, compared with an operating loss of $8.1 million (including a non-cash expense of $1 million related to stock based compensation), or $3.19 per ordinary share, for 2006.

"Rosetta Genomics had a truly remarkable year in 2007, with significant progress, in all fronts of our business, toward meeting patients' unmet medical needs," said Amir Avniel, President and CEO. "The rapid advancements of our diagnostic programs throughout 2007 is expected to lead to the first launch of diagnostic tests in 2008 based on our microRNA technology. I expect 2008 to be a defining year for us, and I am confident we will continue to play a leadi
'/>"/>